E
Exai Bio
Delivering next-generation liquid biopsy platform for the earliest detection and most accurate cancer diagnosis
About Exai Bio
Exai Bio is a pioneering startup operating in the healthcare technology sector, specifically focusing on cancer diagnostics. The company has developed a next-generation RNA-based platform that leverages artificial intelligence (AI) to detect early signs of cancer from a simple blood draw. This innovative approach has the potential to revolutionize the way we detect, diagnose, treat, and ultimately cure cancer.
Exai Bio's primary clients are healthcare providers and medical professionals who are seeking more accurate and efficient methods of diagnosing cancer. The company operates in the rapidly growing market of AI-based healthcare solutions, a sector that is expected to experience significant growth in the coming years due to the increasing integration of technology in healthcare.
The business model of Exai Bio is centered around the development and commercialization of its RNA-based diagnostic platform. The company generates revenue by licensing its technology to healthcare providers and through partnerships with other medical technology companies. Additionally, Exai Bio also profits from the sale of its diagnostic tests to medical institutions.
The company's unique approach of using novel RNA biomarkers and AI to find signals in what appears to others as noise sets it apart from its competitors. This innovative method allows Exai Bio to find actionable clinical insights that were not possible before, thereby providing a more accurate and early diagnosis of cancer.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Palo Alto, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 67.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Genetics and genomics, Core AI, RNA, Spinout, Tech for Hospitals and Clinics
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2022 | $71M | $286M | Undisclosed | ↗ |
| SERIES AOther financing | Dec 2021 | $68M | $270M | Two Sigma Ventures · Casdin Capital · Section 32 | ↗ |
Growth signals
Latest recorded traffic for Exai Bio is 5.8K monthly website visits, up 48.7% over the last three months. Exai Bio's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exai Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exai Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.